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ABSTRACT
The best therapeutic options for serious infections due to daptomycin nonsusceptible Enterococcus faecium (DNSE) 
remain unclear. We report the use of daptomycin for the treatment of DNSE bacteremia. To our knowledge, it is the fırst 
case of DNSE infection which successfully treated with daptomycin monotherapy in the literature. J Microbiol Infect Dis 
2014;4(1): 36-38
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Daptomisine duyarlı olmayan Enterococcus faecium bakteriyemisinde daptomisin tedavisi: 
Olgu sunumu
ÖZET
Daptomisine duyarlı olmayan Enterococcus faecium (DNSE)’a bağlı ciddi enfeksiyonlarda en iyi tedavi seçeneği belirsiz-
dir. Burada DNSE bakteriyemisi olan bir olguda daptomisin kullanımı tecrübemizi paylaştık. Bildiğimiz kadarı ile litera-
türde daptomisin monoterapisi ile başarılı tedavi edilen ilk olgudur.
Anahtar kelimeler: Enterokoklar, kanakımı enfeksiyonu, daptomisin
INTRODUCTION
Bacteremia caused by vancomycin-resistant en-
terococci (VRE) has been associated with higher 
morbidity and mortality than caused by vancomycin 
susceptible enterococci.1 The optimal approach for 
treatment of enterococcal infection due to vanco-
mycin-resistant E. faecium is uncertain.2 Although 
daptomycin has not been approved by the FDA for 
E. faecium, some favor the use of daptomycin for 
treatment of E. faecium infections that are resistant 
in vitro to approved antibiotics.2 Minimum dosing 
for bloodstream infections is 6 mg/kg intravenously 
once daily; in the setting of bloodstream infections 
some favor doses of 8 mg/kg intravenously once 
daily or higher. Higher dosing (8 to 12 mg/kg every 
24 hours) may be more efficacious for life threaten-
ing infections due to E. faecalis or E. faecium.3 Dap-
tomycin has concentration-dependent killing and in 
vivo data have shown that higher doses.4
The knowledge about the emergence of dapto-
mycin nonsusceptible Enterococcus strains and the 
treatment of the associated infections is limited.5 
Daptomycin nonsusceptibility among staphylococci 
has been reported in Turkey.6,7 We describe the first 
case which reported from Turkey of a patient with 
loss of daptomycin susceptibility among enterococ-
ci after daptomycin treatment.
CASE REPORT
In September 2010 a 36-year-old woman admit-
ted to our neurosurgical intensive care unit (ICU) 
because she had a diffuse axonal injury due to a 
traffic accident. A subclavian nontunneled catheter 
was inserted and she was treated medically without 
any surgical intervention. On the ninth day of the 
admission she was found to have fever of 39°C and 
erythema at the catheter exit site. She was consid-
ered to have catheter related infection. Two blood Sevgi D. Y, et al. Daptomycin nonsusceptible Enterococcus bacteremia 37
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cultures were obtained, the subclavian catheter was 
replaced and the catheter tip was sent for culture 
to our Clinical Microbiology Laboratory. Piperacillin-
tazobactam (4.5 gm every 8 hours) intravenously 
was initiated on the same day while the culture result 
was pending. Vancomycin resistant Enterococcus 
faecium was isolated from both blood cultures and 
the catheter tip site. The Bact/Alert 3D (BioMerieux, 
Mercy Etoile, France) blood culture system was 
used. Identification was carried out by BBL CRYS-
TALTM Gram-Positive ID kit (Becton Dickinson, 
ABD). The antibiotic susceptibility performed by Kir-
by-Bauer disc diffusion test revealed resistance to 
penicillin, ampicillin, gentamicin, vancomycin, teico-
planin and rifampin. E test was also performed and 
the MIC breakpoints were found to be as follows: 
vancomycin >32 mg/L, teicoplanin >32 mg/L, line-
zolid 12 mg/L, daptomycin 1.5 mg/L. The strain was 
found to be susceptible to daptomycin. Piperasilin-
tazobactam treatment was discontinued. Daptomy-
cin (6 mg/kg per day) intravenously was initiated. 
The patient became afebrile on the second day of 
the treatment and daptomycin was continued for up 
to ten days. Approximately 15 days later she had 
fever, hypotension, and tachycardia although there 
were no signs of infection at her subclavian catheter 
exit site, the catheter was removed and the catheter 
tip was sent for culture again. Simultaneously two 
blood cultures were also obtained from the patient. 
Cefepime (2 g every 12 h) and daptomycin treat-
ment (6 mg/kg per day) intravenously was initiated. 
The catheter tip culture remained sterile after the 
incubation but Vancomycin resistant Enterococcus 
faecium was isolated from both blood cultures. The 
Bact/Alert 3D (BioMerieux, Mercy Etoile, France) 
blood culture system was used. Identification was 
carried out by BBL CRYSTALTM Gram-Positive ID 
kit (Becton Dickinson, ABD). Cefepime treatment 
was discontinued. The antibiotic susceptibility per-
formed by Kirby-Bauer disc diffusion test revealed 
resistance to penicilin, ampicillin, gentamycin, van-
comycin, teicoplanin and rifampin. The MIC break-
points established for different antibiotics by E test 
were as follows: vancomycin >32 mg/L, teicoplanin 
>32 mg/L, linezolid 32mg/L, daptomycin 8 mg/L. Al-
though the strain was nonsusceptible to daptomycin 
we continued daptomycin 8 mg/kg treatment. We 
didn’t find any vegetations on the performed trans-
thoracic echocardiogram. The patient was consid-
ered to have primary bacteremia. The MIC break-
point for daptomycin of the isolated strain was con-
firmed by a reference laboratory (Quotient Biore-
search, UK) to be 16 mg/L by both E-test and micro 
broth dilution methods. The patient became afebrile 
on the fifth day of treatment and the blood cultures 
obtained on the same day remained sterile until the 
end of the incubation. The treatment was continued 
for 14 days. She was discharged on January 2011 
with full recovery for her diffuse axonal injury and 
without any complications of the bacteremia.
DISCUSSION
Vancomycin resistant enterococci (VRE) are im-
portant cause of nosocomial bloodstream infection 
(BSI).8,9 There are limited treatment options currently 
available for the treatment of VRE infections.8 Dap-
tomycin is a cyclic lipopeptide antibiotic with rapid 
bactericidal activity against drug-resistant bacteria 
including methicillin-resistant Staphylococcus au-
reus and VRE.10 Neither Clinical Laboratory Stan-
dards Institute (CLSI) nor the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) 
committees have defined resistance breakpoints for 
enterococci to daptomycin. EUCAST defined insuf-
ficient evidence to set a breakpoint for enterococ-
ci.11 According to CLSI Enterococcus isolates with 
minimum  inhibitory  concentrations  (MICs)  ≤4  µg, 
determined by broth dilution are considered sus-
ceptible.12 Moreover, enterococci with daptomycin 
MICs >4 µg/ml are considered as non-susceptible 
(DNSE).11 Strains with MICs above the established 
breakpoint are not often encountered. From 2003 
through 2010 there are 23 studies reporting 150 
DNSE. Of these 150 isolates, 140 (93.3%) were 
VRE, nine were vancomycin susceptible entero-
cocci (VSE) and in one (0.7%) case, vancomycin 
susceptibility was not reported.5
Treatment of DNSE isolates was reported in 
nine cases. All cases had underlying diseases im-
pairing the immune functions of the patients, were 
treated with alternative agents other than daptomy-
cin and four of them were cured.5,12 The optimal man-
agement of serious DNSE infection is unknown.5 
Currently there is no available literature comparing 
the efficacy of various doses of daptomycin in rela-
tion to MIC values.13
Daptomycin displays concentration-dependent 
activity that is best characterized by pharmacody-
namic indexes AUC/MIC or Cmax/MIC. The phar-
macodynamics of daptomycin for E. faecium was 
characterized in the neutropenic mouse model. The 
AUC/MIC ratios required for bacteriostatic effect 
ranged from 0.94 to 1.67 for E. faecium. The free 
daptomycin concentrations needed were an aver-
age of one to two times the MIC over 24 hours to 
produce a bacteriostatic effect and two to four times 
the MIC over 24 hours to produce greater than 99% 
killing.4 For the human situation, it can be calculated 
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reached with a dose 8 mg/kg in humans) and as our 
strain had MIC 16 mg/l, AUC/MIC ratio was calcu-
lated to be 53.6.14,15 This value might have been ad-
equate for achieving bactericidal effect in our case.
Our case didn’t have any co-morbidities caus-
ing immune impairment. This may also have con-
tributed for the cure of our patient unlike the other 
reported cases of treatment failure. In our case En-
terococcus faecium was resistant to all other antibi-
otic agents and we treated the patient with dapto-
mycin as we didn’t have any other choice. Although 
there are no defined MIC breakpoints for a resistant 
category for Enterococcus according to CLSI or EU-
CAST, to our knowledge it is the fırst case of DNSE 
infection successfully treated with daptomycin in the 
literature. As a result prospective studies are need-
ed to fully understand the use of daptomycin in the 
treatment of DNSE bacteremia.
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